Suppr超能文献

[长期哮喘治疗的新进展]

[New aspects of long-term asthma therapy].

作者信息

Frank A

出版信息

Wien Med Wochenschr Suppl. 1979;54:1-10.

PMID:34936
Abstract

Asthma is a chronic disease requiring long-term treatment, principally on an ambulant basis. A regimen is described involving all the measures which are practicable in ambulant use--elimination of allergens, hyposensitization and multiple drug treatment with corticosteroids, ACTH, beta-adrenergic agents, anticholinergics, theophylline, sodium cromoglicate and the new compound, ketotifen--taking into account both the aetiology and pathogenesis of the disease and synergistic effects of the available medicines. The immediate aim is to give the patient sustained freedom from symptoms. Once this has been achieved, multiple drug treatment can gradually give way to a protective/prophylactic regimen. Two-and-a-half years of experience with the oral antianaphylactic histamine-release inhibitor, ketotifen, have convinced us that this new drug is very suitable both as part of a multiple-drug regimen designed to bring the condition under control, and as a prophylactic for subsequent protection against further attacks. An additional advantage of ketotifen is the very low incidence of adverse reactions. Brief reference is also made to the treatment of infections and to the role of psychotherapy, breathing exercises and sport in asthma therapy.

摘要

哮喘是一种需要长期治疗的慢性疾病,主要在门诊进行。本文描述了一种治疗方案,该方案涉及在门诊治疗中可行的所有措施——消除过敏原、脱敏治疗以及使用皮质类固醇、促肾上腺皮质激素、β-肾上腺素能药物、抗胆碱能药物、茶碱、色甘酸钠和新化合物酮替芬进行多种药物治疗——同时考虑到疾病的病因和发病机制以及现有药物的协同作用。直接目标是使患者持续无症状。一旦实现这一目标,多种药物治疗可逐渐让位于保护性/预防性治疗方案。对口服抗过敏性组胺释放抑制剂酮替芬进行的两年半的试验让我们确信,这种新药非常适合作为旨在控制病情的多种药物治疗方案的一部分,也适合作为预防后续再次发作的预防性药物。酮替芬的另一个优点是不良反应发生率非常低。本文还简要提及了感染的治疗以及心理治疗、呼吸练习和运动在哮喘治疗中的作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验